FATE FY 2022 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$96M+72.4% YoY

Gross Profit

$83M85.7% margin

Operating Income

-$308M-320.2% margin

Net Income

-$282M-292.5% margin

EPS (Diluted)

$-2.91

Cash Flow

Operating Cash Flow

-$248M

Free Cash Flow

-$284M

Stock-Based Comp.

$79M

Balance Sheet

Total Assets

$706M

Total Liabilities

$222M

Stockholders' Equity

$484M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$96M	$56M	+72.4%
Gross Profit	$83M	$50M	+65.1%
Operating Income	-$308M	-$217M	-42.1%
Net Income	-$282M	-$212M	-32.8%